Meta-analysis of gemcitabine plus nab-paclitaxel combined with targeted agents in the treatment of metastatic pancreatic cancer

BACKGROUND: Gemcitabine plus nab-paclitaxel (GA) is a commonly used first-line treatment regimen for metastatic pancreatic cancer, and many studies will add a novel targeted agent to this regimen for improving patient survival rate. However, the clinical effectiveness of GA is the most controversial...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Zhong-Hui, Ma, Yin-Jie, Jia, Zong-Hang, Weng, Yue-Yan, Zhang, Ping, Zhu, Shi-Jie, Wang, Fang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2022
Materias:
Meta-Analysis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9516936/
https://www.ncbi.nlm.nih.gov/pubmed/36186177
http://dx.doi.org/10.12998/wjcc.v10.i27.9703

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9516936/
https://www.ncbi.nlm.nih.gov/pubmed/36186177
http://dx.doi.org/10.12998/wjcc.v10.i27.9703

Ejemplares similares